1. Introduction {#sec1-brainsci-09-00183}
===============

Metabotropic glutamate 5 receptors (mGlu~5~ receptors) represent a viable target for the treatment of alcohol-use disorders (AUDs) and negative affective phenotypes, and their use for each of these was recently independently reviewed \[[@B1-brainsci-09-00183],[@B2-brainsci-09-00183],[@B3-brainsci-09-00183]\]. However, negative affective states are also known to play a role in AUDs, as they are a primary driver of drinking and relapse behaviors \[[@B4-brainsci-09-00183]\]. "Negative affect" is a defined set of negative emotional states, which underlie many highly comorbid psychiatric disorders, including depression and anxiety \[[@B5-brainsci-09-00183]\]. Preclinically, negative affective symptoms can be clustered into changes in reinforcer seeking and consumption, behavioral despair, anxiety-like activity, increased threat monitoring, hypervigilance, and home cage activity \[[@B6-brainsci-09-00183],[@B7-brainsci-09-00183],[@B8-brainsci-09-00183]\]. These negative affective states might heighten sensitivity to alcohol-related cues and drive relapse \[[@B9-brainsci-09-00183],[@B10-brainsci-09-00183]\]. Moreover, disorders that encompass negative affect are more prevalent in women and are highly comorbid with AUDs \[[@B11-brainsci-09-00183],[@B12-brainsci-09-00183]\]. The current review will synthesize research that has investigated the role of mGlu~5~ receptors in alcohol use and negative affect, as well as identify gaps in the literature, particularly in regard to sex differences.

This review will primarily integrate the work involved in mGlu~5~ receptor modulation and its ability to regulate ethanol intake, the salience of ethanol-associated cues and contexts, and ethanol-induced behavioral despair and anxiety-like activity. mGlu~5~ and mGlu~1~ receptors comprise the group 1 metabotropic glutamate receptor class (mGlu~1/5~ receptors), which are Gα~q/11~-coupled receptors that regulate synaptic plasticity \[[@B13-brainsci-09-00183]\]. In these studies, mGlu~5~ receptors have been modulated using genetic manipulations or pharmacological tools. The role of global central nervous system knockout of mGlu~5~ receptors in drug use was first reported by Chiamulera et al. \[[@B14-brainsci-09-00183]\], who demonstrated that mGlu~5~-receptor-null mice do not acquire cocaine self-administration. Many tools beyond global knockout now exist, including cell-specific knockout \[[@B15-brainsci-09-00183],[@B16-brainsci-09-00183]\], mGlu~5~ receptor deficiency \[[@B17-brainsci-09-00183]\], and mGlu~5~ receptor point mutations \[[@B18-brainsci-09-00183],[@B19-brainsci-09-00183]\]. These studies used allosteric modulators, which are ligands that bind to a receptor site that is distinct from the endogenous or orthosteric ligand, as pharmacological interventions. Allosteric modulators negatively or positively regulate the activity of a receptor in the presence of its orthosteric ligand, but might also act as allosteric agonists or inverse agonists. mGlu~5~ receptor allosteric modulators discussed in the current review include the positive allosteric modulator (PAM), 3-Cyano-*N*-(1,3-diphenyl-1*H*-pyrazol-5-yl)benzamide (CDPPB), and the negative allosteric modulators (NAM), 2-Methyl-6-(phenylethynyl)pyridine (MPEP) and 3-((2-Methyl-1,3-thiazol-4-yl)ethynyl)pyridine (MTEP). CDPPB has been noted for its interaction with the MPEP binding site, as well as its ability to mediate aberrant phenotypes associated with dysregulation of the ionotropic glutamate N-methyl-D-aspartate receptor (NMDAR) \[[@B20-brainsci-09-00183]\]. It should be noted that MPEP and MTEP both act as inverse agonists to block the constitutive activities of the mGlu~5~ receptors in vivo \[[@B21-brainsci-09-00183],[@B22-brainsci-09-00183]\]. They also differ in their selectivity for mGlu~5~ receptors. Although MPEP is selective for mGlu~5~ receptors at lower doses, it becomes less selective as the dose increases and acts at other receptors, including NMDARs. The more recently developed MTEP conserves selectivity for mGlu~5~ receptors without demonstrating off target activity at NMDARs \[[@B2-brainsci-09-00183]\]. All of these drugs have been implicated as potential therapeutic treatments to alleviate negative affective symptomology and drug-seeking behavior \[[@B2-brainsci-09-00183],[@B20-brainsci-09-00183]\].

2. Ethanol Intake {#sec2-brainsci-09-00183}
=================

The ability of mGlu~5~ receptors to modulate ethanol intake has recently been extensively reviewed \[[@B3-brainsci-09-00183]\]. Generally, treatment with mGlu~5~ receptor NAMs results in decreased ethanol consumption and responding in 24 h access 2-bottle choice, limited access, and operant drinking paradigms (see [Table 1](#brainsci-09-00183-t001){ref-type="table"}). With the exception of Adams et al. \[[@B23-brainsci-09-00183]\] systemic mGlu~5~ receptor modulation consistently reduced drinking across a range of paradigms, species, and strains. Conversely, antagonism of mGlu~1~ receptors via systemic treatment of CPCCOEt was less effective at reducing ethanol intake or resulted in off-target effects, including reduced locomotion or sucrose intake \[[@B24-brainsci-09-00183],[@B25-brainsci-09-00183],[@B26-brainsci-09-00183]\]. Although higher doses of mGlu~5~ receptor NAMs also reduced locomotion and sucrose intake in some studies, these doses are beyond the efficacious dose for ethanol intake \[[@B26-brainsci-09-00183],[@B27-brainsci-09-00183],[@B28-brainsci-09-00183],[@B29-brainsci-09-00183]\]. This further indicates that mGlu~5~ receptor-targeted treatment could be well tolerated as a clinical intervention compared to mGlu~1~-receptor pharmacological interventions. Finally, systemic MPEP prevents the alcohol deprivation effect following free-choice and operant ethanol access \[[@B24-brainsci-09-00183],[@B30-brainsci-09-00183]\]. However, its efficacy may be reduced over repeated deprivation cycles \[[@B24-brainsci-09-00183]\], indicating the necessity of using alcohol-dependent models. Repeated alcohol exposure and withdrawal cycles promote neuroadaptations \[[@B9-brainsci-09-00183],[@B10-brainsci-09-00183]\], which might lessen the efficacy of a drug that was initially promising.

Due to the allosteric properties of CDPPB, MPEP, and MTEP, it is important to consider whether alcohol exposure affects receptor availability and how that could inform the appropriate pharmacological treatment for different populations with AUDs. Using the highly potent and selective mGlu~5~ receptor NAM ^18^\[F\]-FPEB in PET scans, mGlu~5~ receptor availability has been demonstrated to be relatively stable in healthy humans over a 6 month period \[[@B38-brainsci-09-00183]\]. However, higher doses of MTEP are required to reduce ethanol consumption in alcohol-dependent rats \[[@B36-brainsci-09-00183]\], and alcohol has been demonstrated to alter mGlu~5~ receptor availability in both humans and rodents. In rodents, relatively low doses of forced ethanol over a two-week period enhances striatal, hippocampal, and cortical mGlu~5~ receptor availability compared to saline controls \[[@B39-brainsci-09-00183]\]. In contrast, chronic free-choice access to ethanol decreases mGlu~5~ receptor availability in the hippocampus and amygdala, when compared to baseline levels \[[@B40-brainsci-09-00183]\]. These PET studies lend support to the hypothesis that extensive alcohol exposure shifts the availability of mGlu~5~ receptors, thereby resulting in reduced efficacy of MTEP to reduce drinking in dependent rats \[[@B36-brainsci-09-00183]\]. Similar results have been found in humans, where increased mGlu~5~ receptor availability primarily in cortical regions is associated with "feeling high" during alcohol exposure in healthy, low-drinking humans \[[@B41-brainsci-09-00183]\]. Alcohol-dependent individuals have lower mGlu~5~ receptor availability compared to controls, across many striatal and cortical regions \[[@B42-brainsci-09-00183]\]. Availability of mGlu~5~ receptors recovers in a site- and time-dependent manner, across 6 months of alcohol abstinence, except in the hippocampus, accumbens, and thalamus \[[@B43-brainsci-09-00183]\]. This reduced mGlu~5~ receptor availability in alcohol-dependent subjects may be mediated by comorbid substance use, such as smoking status \[[@B44-brainsci-09-00183]\]. Non-smoking alcohol-dependent males show increased, not decreased, mGlu~5~ receptor availability in cortical regions and the amygdala at one month of abstinence \[[@B44-brainsci-09-00183]\]. Notably, reduced mGlu~5~ receptor availability is related to increased alcohol craving, regardless of smoking status \[[@B42-brainsci-09-00183],[@B43-brainsci-09-00183],[@B44-brainsci-09-00183]\]. Collectively, this work points toward dynamic regulation of mGlu~5~ receptor availability across early alcohol use, chronic alcohol use, alcohol abstinence, and comorbid drug use. It is still unclear from this work if there is a causal relationship between receptor availability and excessive ethanol drinking, dependence, and craving. Genetic variants in the *mGluR-eEf2*-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) pathway, including *GRM5*, predict alcohol intake \[[@B45-brainsci-09-00183]\] and might independently regulate receptor availability. These findings complement the pharmacological studies mentioned above in pointing towards differences in mGlu~5~ receptor availability and pharmacological efficacy, depending on the type of alcohol exposure and genetic predisposition.

The studies detailed in [Table 1](#brainsci-09-00183-t001){ref-type="table"} primarily focused on adult males; however, there is strong clinical evidence that supports the need to observe ethanol consumption in females and adolescents following mGlu~5~ receptor modulation. Adolescence is the time when alcohol use is typically initiated, and this use is known to be one of the strongest predictors for later development of AUDs \[[@B12-brainsci-09-00183],[@B46-brainsci-09-00183]\]. While males are likely to use alcohol as positive reinforcement, females are more likely to use alcohol as a negative reinforcement coping mechanism \[[@B47-brainsci-09-00183]\]. Females are 2--3 times more likely to develop stress and anxiety disorders that might contribute to negative affective states, and this divergence of risk coincides with adolescent alcohol exposure \[[@B11-brainsci-09-00183]\]. It has been demonstrated that women have lower mGlu~5~ receptor availability across many brain regions \[[@B48-brainsci-09-00183]\], thereby indicating that there may be sex-differences in response to allosteric modulators. Cozzoli et al. \[[@B31-brainsci-09-00183]\] investigated the interaction of both adolescence and sex on ethanol intake. MTEP effectively reduced ethanol intake in both adolescent and adult male and female mice. However, during protracted abstinence (21 days), prior MTEP treatment showed no long-term effects on ethanol consumption in males of either age group. Females exposed to MTEP pretreatment during adolescence reduced their ethanol consumption in adulthood, whereas their adult-treated counterparts showed increased alcohol consumption. In another study, Parkitna et al. \[[@B15-brainsci-09-00183]\] demonstrated that knockdown of mGlu~5~ receptors on D1 neurons did not alter acquisition of ethanol intake under a continuous access instrumental response paradigm in females, but did inhibit an ethanol deprivation ramp-up during forced abstinence. Although males of the same strain demonstrated alcohol deprivation ramp-up of intake, it was not altered by mGlu~5~ receptor knockdown \[[@B16-brainsci-09-00183]\]. However, the male and female paradigms differed in length of alcohol history and instrumental response criteria, making it difficult to determine if the disparate findings were due to methodological- or sex-differences. Although mGlu~5~ receptor NAMs have not yet been investigated for their potential to alleviate AUD and comorbid symptomology, multiple treatments that target this system with minimal side effects have been developed for clinical use \[[@B49-brainsci-09-00183]\]. The preclinical studies indicate that alcohol duration, length of abstinence, age, and sex are all-important considerations in judging the effectiveness of mGlu~5~ receptor NAMs.

3. Ethanol-Associated Cues and Contexts {#sec3-brainsci-09-00183}
=======================================

The role of mGlu~5~ receptors in learning and memory of discrete and contextual cues has been well documented. mGlu~5~ receptor activity contributes to neural plasticity via both long-term depression (LTD), as well as long-term potentiation (LTP) via mGlu~5~-NMDAR interactions discussed in [Section 6](#sec6-brainsci-09-00183){ref-type="sec"} \[[@B13-brainsci-09-00183],[@B50-brainsci-09-00183]\]. In rodent models of non-dependent ethanol intake, mGlu~5~ receptor modulation effectively reduces the salience of ethanol-associated cues and contexts when administered following the cue--ethanol association (see [Table 2](#brainsci-09-00183-t002){ref-type="table"}). The ability to modulate the salience of ethanol-associated cues and contexts, plays an important role in reducing susceptibility to relapse, making it a critical target for pharmacological intervention \[[@B51-brainsci-09-00183],[@B52-brainsci-09-00183]\]. Two paradigms have been primarily used to observe the role of mGlu~5~ receptors in ethanol-associated cues and contexts---ethanol cue-induced reinstatement and conditioned place preference (CPP).

With the exception of Adams et al. \[[@B23-brainsci-09-00183],[@B57-brainsci-09-00183]\], systemic and site-specific negative allosteric modulation of mGlu~5~ receptors was found to reduce cue-induced reinstatement in the presence of discrete cues, such as a light cue \[[@B53-brainsci-09-00183],[@B54-brainsci-09-00183],[@B55-brainsci-09-00183]\], or diffuse contextual stimuli, such as an olfactory scent \[[@B30-brainsci-09-00183]\]. Contextual cues have been posited as more analogous to cues that induce drug craving and seeking in humans than discrete cues, due to their role in indicating general drug availability, transfer of salience, and the difficulty involved in extinguishing these cues \[[@B52-brainsci-09-00183]\]. Although Adams and colleagues \[[@B23-brainsci-09-00183],[@B57-brainsci-09-00183]\] partially contributed their null findings to the low dose of MTEP used, it is important to note that their cue-induced reinstatement paradigm utilized a contextual scent to signal ethanol availability and inbred, high-alcohol-preferring iP rats. Using a discrete-cue paradigm, mGlu~5~ receptor modulation was found to readily block cue-induced reinstatement at a relatively low dose in iP rats \[[@B55-brainsci-09-00183]\]. Therefore, it might be speculated that a genetic predisposition for alcohol preference makes animals resilient to pharmacological intervention, to reduce particularly salient ethanol-associated cues. Without the investigation of higher drug doses in the iP rats, it cannot be concluded whether these disparate results were due to less sensitivity to mGlu~5~ receptor intervention under contextual cue paradigms, or whether mGlu~5~ receptors only play a role in discrete-cued reinstatement when there is a genetic predisposition to consume ethanol.

CPP, which quantifies the reinforcing value of ethanol by observing the amount of time spent in an ethanol-paired context, can be broken down into the cue/context learning phase (acquisition) and the expression of the learned association \[[@B52-brainsci-09-00183]\]. Pharmacologically or genetically reducing the activity of mGlu~5~ receptors results in impaired ethanol CPP, indicating that mGlu~5~ receptor activity contributes to the associating contexts, with ethanol. Notably, this effect appears to be restricted to the expression \[[@B25-brainsci-09-00183],[@B56-brainsci-09-00183],[@B58-brainsci-09-00183]\] but not acquisition of CPP \[[@B56-brainsci-09-00183],[@B59-brainsci-09-00183]\]. In the acquisition studies, drug was administered prior to ethanol during the contextual-pairing sessions, whereas drug was administered without any ethanol on board during the expression test sessions. This might indicate that mGlu5 receptor modulation is not able to overcome the salience of ethanol exposure as it occurs, but rather it blocks the recall of ethanol-associated cues.

In direct opposition to the current studies, it has been reported that mGlu~5~ receptor NAMs often inhibit the extinction of contextual and spatial memories, whereas positive modulation enhances extinction \[[@B60-brainsci-09-00183],[@B61-brainsci-09-00183],[@B62-brainsci-09-00183],[@B63-brainsci-09-00183],[@B64-brainsci-09-00183]\]. Notably, these studies consist primarily of aversive learning conditions, such as avoidance learning, startle response, and fear conditioning. Similar to the currently discussed findings on ethanol context and cues, negative mGlu~5~ receptor modulation has been shown to block context-paired locomotor conditioning to cocaine and methamphetamine CPP \[[@B65-brainsci-09-00183],[@B66-brainsci-09-00183]\]. Acknowledging the divergent effects of negative mGlu~5~ receptor modulation on cues and contexts associated with positive versus negative stimuli is important. In states of dependence and withdrawal, positive ethanol-associated cues might transfer their association to negative affective states. Therefore, these once positive cues might be more similar to the aversive cues that are enhanced by negative mGlu~5~ receptor modulation. Sidhpura et al. \[[@B36-brainsci-09-00183]\] demonstrated that, although MTEP was still effective at blocking stress-induced reinstatement in dependent rats, it was more effective in non-dependent rats. mGlu~5~ receptor NAMs might also be an insufficient treatment for people experiencing an ethanol relapse. Positive mGlu5 modulation has been demonstrated to rescue impaired spatial learning following heavy ethanol exposure \[[@B67-brainsci-09-00183]\], indicating its safety and efficacy in models of dependence. Although the studies discussed within this section favor negative mGlu~5~ receptor modulation for mediating ethanol-associated cues and contexts, positive mGlu~5~ receptor modulation might be a better course of treatment under aversive states associated with alcohol withdrawal and relapse.

Females were not included in any of the discussed studies that observed cue-induced cue reinstatement. In rodents, acute pharmacological stress significantly enhances cue-induced ethanol reinstatement in females, but not males \[[@B68-brainsci-09-00183]\]. In humans, stress has not been demonstrated to enhance ethanol craving or relapse to a greater degree in females than males. However, these human studies either did not report estradiol levels or estrous status \[[@B69-brainsci-09-00183],[@B70-brainsci-09-00183]\], or restricted female testing to periods when circulating estradiol levels were low \[[@B71-brainsci-09-00183]\]. In rodents, circulating estradiol levels were significantly positively correlated with the magnitude of stress-induced reinstatement \[[@B68-brainsci-09-00183]\]. Further, females demonstrate an enhanced ethanol CPP that is dependent upon circulating hormones \[[@B72-brainsci-09-00183]\], as well as alterations in drug efficacy to reduce ethanol intake based on estrous status \[[@B73-brainsci-09-00183]\]. These data indicate that circulating hormones mediate the salience of cues and stress on ethanol-associated activity and should be included in human female studies. There is support for direct interaction of mGlu~1/5~ receptors and estrogen receptors (ER) signaling (see [Section 6](#sec6-brainsci-09-00183){ref-type="sec"}). This convergence of signaling cascades might indicate that mGlu~5~ receptor modulation would be a particularly salient treatment in female populations.

4. Behavioral Despair {#sec4-brainsci-09-00183}
=====================

Behavioral despair, or anhedonic activity, is observed in animal models that represent depressive-like behavior. Although many animal models of behavioral despair exist---including reduction in intake of appetitive reinforcers, the forced swim test, the tail suspension test, social interaction, and response to novelty \[[@B8-brainsci-09-00183],[@B74-brainsci-09-00183]\]---few have been observed following ethanol administration and/or mGlu~5~ receptor manipulation (see [Table 3](#brainsci-09-00183-t003){ref-type="table"}). Of these studies, the forced swim task has been the predominantly used paradigm. This task observes the time spent immobile in a container of water. Time spent immobile is decreased by treatment with antidepressants, indicating translational relevance \[[@B74-brainsci-09-00183]\]. Limited access ethanol in adult male mice reliably induces behavioral despair in the forced swim test 24 h into withdrawal \[[@B75-brainsci-09-00183],[@B76-brainsci-09-00183],[@B77-brainsci-09-00183]\]. This effect is rescued by systemic MTEP treatment, but not site-specific treatment targeting the NAc shell \[[@B75-brainsci-09-00183],[@B76-brainsci-09-00183]\]. Conversely, systemic treatment with the mGlu~5~ receptor PAM, CDPPB, exacerbates the effect of ethanol withdrawal on behavioral despair \[[@B75-brainsci-09-00183]\]. Adolescent ethanol exposure, however, does not result in a behavioral despair phenotype in male mice 24 h into withdrawal. In contrast, CDPPB administration is able to induce a behavioral despair phenotype in water drinking controls \[[@B75-brainsci-09-00183]\]. Interestingly, protracted withdrawal from adolescent alcohol does result in a behavioral despair phenotype \[[@B76-brainsci-09-00183]\], but it is not known if it can be rescued via systemic mGlu~5~ receptor modulation.

Although mGlu~5~ receptors appear to be a promising target for rescuing behavioral despair induced by ethanol exposure, these studies suffer from lack of diversity in tests, ethanol exposure paradigms, sex, and age. All studies discussed in this section used a 14-day drinking-in-the-dark exposure in male B6 mice. No studies have observed the effects of ethanol dependence, prolonged ethanol exposure, or protracted ethanol withdrawal in adulthood on behavioral despair. These studies are necessary to accurately capture the ability of mGlu~5~ receptor modulation to mediate the negative-affective withdrawal phenotype that promotes relapse susceptibility. Male and female rodents also express behavioral despair in a sex-dependent manner. For example, females are susceptible to the forced swim test, but relatively resilient to psychosocial models of despair \[[@B74-brainsci-09-00183]\]. The forced swim task suffers from many criticisms, which include the lack of translational value for treatment development, dependence on physical activity, and differing survival strategies to conserve energy \[[@B74-brainsci-09-00183],[@B78-brainsci-09-00183]\]. However, the forced swim test is high-throughput, and engages overlapping neural circuitry with humans suffering from depression \[[@B74-brainsci-09-00183]\], making it a valuable tool when paired with other behavioral despair tests. Complementary tasks may include seeking and consumption of non-drug reinforcers, tail suspension task, social interaction, response to novelty, and observation of normative home-cage activities such as grooming \[[@B6-brainsci-09-00183],[@B8-brainsci-09-00183]\]. As these tests result in sexually distinct phenotypes that are not consistent between tasks \[[@B8-brainsci-09-00183]\], it is important to include multiple behavioral paradigms to observe how ethanol alters the complete behavioral despair phenotype. Finally, as mGlu~5~ receptor modulation shows promise in these studies, it should be examined at both younger and older ages, following alcohol exposure, dependence, and protracted withdrawals. Depression at both young and old age is associated with poor outcomes and limited response to traditional antidepressants \[[@B74-brainsci-09-00183]\], making the mGlu~5~ receptors a promising target.

mGlu~5~ receptors have been extensively implicated in major depression disorder (MDD) at the clinical and preclinical levels, as recently reviewed by Esterlis et al. \[[@B79-brainsci-09-00183]\]. Similar to the studies discussed that have observed mGlu~5~ receptor availability in alcohol use disorders (see [Section 2](#sec2-brainsci-09-00183){ref-type="sec"}), studies observing those with MDD without alcohol and substance use disorders have reported mixed findings. One study has reported increased post-mortem *Grm5* expression in the locus coeruleus of MDD individuals, noting the important role of locus coeruleus excitability in MDD \[[@B80-brainsci-09-00183]\]. Studies reporting reduced mGlu~5~ receptor availability in those with MDD have been conducted in non-smoking populations \[[@B81-brainsci-09-00183],[@B82-brainsci-09-00183]\], whereas those that reported no differences overwhelmingly included smoking individuals \[[@B83-brainsci-09-00183],[@B84-brainsci-09-00183],[@B85-brainsci-09-00183],[@B86-brainsci-09-00183]\]. Smoking status also mediates the relationship between mGlu~5~ receptor availability and alcohol use, but it appears that smoking is responsible for the reduced mGlu~5~ receptor availability in heavy drinkers \[[@B44-brainsci-09-00183]\]. Although the relationships between mGlu~5~ receptor availability and smoking status in heavy alcohol use and MDD are divergent, it is still notable that smoking status might alter response to mGlu~5~ receptor modulators as behavioral treatments in each of these populations. Ketamine, which was recently approved by the FDA for treatment-resistant MDD, rapidly reduces availability of mGlu~5~ receptors in non-smokers with MDD and in healthy controls. The magnitude of reduction of receptor availability in the hippocampus was positively correlated with a reduction in symptoms of depression \[[@B81-brainsci-09-00183]\]. This relationship between mGlu~5~ receptor availability and depression symptomology has also been reported in non-smoking individuals not treated with ketamine \[[@B82-brainsci-09-00183]\]. Although the effects of ketamine have been linked to mGlu~5~ receptors, directly targeting mGlu~5~ receptors with NAMs has not been demonstrated to treat symptoms of MDD in clinical trials \[[@B87-brainsci-09-00183],[@B88-brainsci-09-00183]\]. Notably, the primary outcome of these studies was the Montgomery--Åsberg Depression Rating Scale (MADRS), which is clinician-rated during an interview session. However, when patients are asked to self-report, negative mGlu~5~ receptor modulation significantly improves depressive symptomology and quality of life when paired with a traditional antidepressant \[[@B88-brainsci-09-00183]\]. These results indicate that treatment with mGlu~5~ receptor modulators might alleviate internal feelings of depressive symptomology that promote excessive alcohol intake.

5. Anxiety-Like Activity {#sec5-brainsci-09-00183}
========================

Anxiety-like activity is a major component of negative affective behavior, as well as a primary driver of stress and stress-induced relapse \[[@B5-brainsci-09-00183],[@B10-brainsci-09-00183]\]. Several studies have observed the ability of mGlu~5~ receptor modulation to alter alcohol-induced unconditioned anxiety-like behavior across a range of paradigms. These paradigms include approach--avoidance conflict tasks (elevated plus maze, light/dark box, and the open field task) \[[@B89-brainsci-09-00183]\], as well as the marble burying task. Although marble burying is poorly correlated with traditional measures of anxiety, it is regarded as a perseverative, investigative activity that can be pharmacologically manipulated \[[@B90-brainsci-09-00183],[@B91-brainsci-09-00183]\]. With few exceptions \[[@B58-brainsci-09-00183],[@B75-brainsci-09-00183]\], all papers detailed in [Table 4](#brainsci-09-00183-t004){ref-type="table"} observed increases in anxiety-like activity following ethanol exposure, which were overwhelmingly rescued by mGlu~5~ receptor NAM administration.

The efficacy of mGlu~5~ receptor NAMs to reduce heightened anxiety-like activity is consistent across ethanol i.p. administration \[[@B92-brainsci-09-00183]\], ethanol liquid diet \[[@B93-brainsci-09-00183]\], and free-choice limited ethanol access \[[@B75-brainsci-09-00183],[@B76-brainsci-09-00183]\]. Within adult animals, the findings were also consistent across behavioral assays. This is notable due to the poor predictive validity of each of these tests on their own \[[@B89-brainsci-09-00183]\]. Further, in the absence of alcohol, mGlu~5~ receptor modulation is a promising target for treatment of anxiety disorders. A majority of reports using mGlu~5~ receptor modulation to alter anxiety-like activity report anxiolytic responses, whereas serotonergic, endocannabinoid, neuropeptide, and other glutamatergic targets often report inactivity of the tested compounds, or even anxiogenic activity \[[@B94-brainsci-09-00183],[@B95-brainsci-09-00183]\]. In these studies, mGlu~5~ receptor modulation had minimal effects on anxiety-like activity in control mice, contrary to its predominately anxiolytic profile in many assays \[[@B95-brainsci-09-00183]\]. One reason for this might be that these tests employed parameters that evoked low baseline anxiety levels (such as low light intensity) to be able to detect heightened anxiety-like activity present in alcohol exposed mice. In typical anxiety-like assays, ceiling levels of anxiety are often provoked by bright lights, aversive or threatening stimuli, or conflict \[[@B95-brainsci-09-00183]\]. As such, the current studies indicate that targeting mGlu~5~ receptors might normalize maladaptive behavior that is present following alcohol use, without disrupting normal system function.

Although the studies examining anxiety-like activity use a wide range of ethanol exposures and behavioral outcomes, they still suffer from limitations of age and sex, with adult males being the primary demographic studied. With the exception of Lee et al. \[[@B75-brainsci-09-00183]\], mGlu~5~ receptor modulation was able to rescue anxiety-like phenotypes observed within 48 h of the last ethanol vapor. Lee et al. \[[@B75-brainsci-09-00183]\] were unable to demonstrate an enhanced anxiety-like profile in adolescent males following ethanol exposure. However, it has been well-documented that alcohol exposure during adolescence kindles anxiety-like behavior during protracted withdrawal, as mice age into adulthood \[[@B75-brainsci-09-00183],[@B96-brainsci-09-00183],[@B97-brainsci-09-00183],[@B98-brainsci-09-00183],[@B99-brainsci-09-00183],[@B100-brainsci-09-00183],[@B101-brainsci-09-00183]\]. In the context of preventing negative-affect-induced relapse, it is necessary to investigate whether mGlu~5~ receptor modulation might also rescue enhanced anxiety-like activity that occurs during extensive ethanol abstinence. Similarly, females may be especially sensitive to anxiety during periods of abstinence \[[@B11-brainsci-09-00183],[@B47-brainsci-09-00183]\], with protracted withdrawal from adolescent alcohol resulting in enhanced anxiety-like and despair behavior \[[@B99-brainsci-09-00183],[@B102-brainsci-09-00183]\]. These results highlight the need to observe the ability of mGlu~5~ receptor modulation to alter anxiety-like activity in males and females during protracted withdrawal from alcohol.

6. Synaptic Plasticity {#sec6-brainsci-09-00183}
======================

While the studies discussed up to this point have focused on the behavioral outcomes of mGlu~1/5~ receptor activation, much is also known about the impacts of the cellular mechanisms of these receptors by drugs of abuse and negative affect. mGlu~1/5~ receptors are located postsynaptically or perisynaptically and are anchored to the postsynaptic density by interactions with Homer and SHANK. While mGlu~1/5~ receptors are key regulators of excitatory synaptic plasticity through both LTD and LTP, the following discussion focuses on mGlu1/5 regulation of LTD. Generally in regions like the bed nucleus of the stria terminalis (BNST) and striatum, mGlu~1/5~ receptor activation leads to phospholipase C (PLC) enhancement of PIP~2~, which in turn activates two divergent downstream pathways. One involves the activation of IP~3~ pathway and release of endoplasmic reticulum Ca^2+^ subsequent protein kinase C (PKC), mitogen-activated protein kinase kinase (MEK), and Erk1/2 activation, which can ultimately activate Arc. Secondly, activation of the IP~3~ pathway produces diacyl-glycerol (DAG), which is then acted upon by PLC and DAG lipase (DAGL) to produce the endocannabinoid, 2-AG. In LTD, the initial (early) phase of this LTD is initiated by generation of 2-AG, which is released from the postsynaptic neuron and activates presynaptic type 1 cannabinoid receptors (CB1 receptor). The activation of presynaptic CB1 receptors produces a reduction in glutamate release or an enhancement of GABA release. The maintenance (late) phase of this LTD is initiated through the actions of the IP3 pathway (discussed above) that ultimately produces the internalization of AMPARs \[[@B13-brainsci-09-00183]\]. The reliance on a raise in postsynaptic Ca^2+^ and subsequent activation of PKC or PLC, as well as the involvement of an endocannabinoid signaling, differ by brain region (reviewed in \[[@B13-brainsci-09-00183]\]). Additionally, the mode of LTD induction \[drug induced via (S)-3, 5-dihydroxyphenylglycine (DHPG), paired-pulse-induces, or frequency-induced\] is also thought to influence the reliance on certain mechanisms (reviwed in \[[@B13-brainsci-09-00183]\]). Further the anatomical contributions of mGlu~1~ receptors versus mGlu~5~ receptors differ by brain region.

The extended amygdala is a collection of brain structures including the nucleus accumbens shell (NAc shell), the bed nucleus of the stria terminalis (BNST), and the central nucleus of the amygdala (CeA). These brain structures are known to play critical roles in in the modulation of negative affect and stress, particularly in the context of withdrawal \[[@B4-brainsci-09-00183]\]. In the BNST of male mice, mGlu~1/5~ receptor-mediated LTD is disrupted by chronic cocaine during both acute withdrawal and prolonged abstinence \[[@B103-brainsci-09-00183],[@B104-brainsci-09-00183]\]. This cocaine-induced mGlu~1/5~ receptor-mediated LTD disruption is manifested by internalization of GluA2-containing AMPARs (calcium-impermeable), followed by replacement with calcium-permeable-AMPARs in the ventral tegmental area (VTA) and NAc \[[@B105-brainsci-09-00183],[@B106-brainsci-09-00183],[@B107-brainsci-09-00183],[@B108-brainsci-09-00183]\]. Outside the extended amygdala, a similar disruption of mGlu~1/5~ receptor-mediated LTD is also found in the hippocampus during acute withdrawal from chronic ethanol vapor in male mice. In the CeA, there is a role for mGlu~1/5~-Homer signaling on ethanol binge-drinking \[[@B34-brainsci-09-00183]\]. A large body of literature from the Szumlinski lab finds that mGlu~1/5~ receptor signaling effects on ethanol are mediated through the interaction with Homer 2 \[[@B18-brainsci-09-00183],[@B34-brainsci-09-00183],[@B109-brainsci-09-00183],[@B110-brainsci-09-00183],[@B111-brainsci-09-00183],[@B112-brainsci-09-00183],[@B113-brainsci-09-00183]\]. Recently, this same group expanded on this work to find that Erk phosphorylation enhances mGlu~5~-Homer interaction in the BNST and this action attenuates ethanol drinking \[[@B19-brainsci-09-00183]\].

This mGlu~5~ receptor signaling mechanism was also found to be critical for estradiol-driven potentiation of psychostimulant-induced behaviors in female rodents \[[@B114-brainsci-09-00183],[@B115-brainsci-09-00183]\]. Estradiol activates ERα through activation of mGlu~1/5~ receptors, thereby activating CREB and phosphorylated PLC through MAPK, independent of glutamate activation. Estradiol-induced CREB phosphorylation is differentially mediated depending on the brain region. mGlu~5~ receptor-dependent regions include the dorsal striatum and NAc core, whereas the NAc shell is mGlu~1a~ receptor-dependent. Estradiol's interactions with mGlu~1/5~ receptors also site-specifically alters brain morphology, decreasing dendritic spines in the NAc core while increasing dendritic spines in the NAc shell. Rodent models of chronic cocaine use have demonstrated that females have fast acquisition, enhanced escalation, and greater reinstatement. ER/mGlu receptor signaling is thought to be responsible for a majority of the sex differences in cocaine behaviors and the neural transmission cocaine phenotypes elicited in females \[[@B116-brainsci-09-00183]\]. Given the efficacy of mGlu~5~ receptor modulation in males and the role of female sex hormones contributing to these behaviors in the cocaine literature, it might be expected that females would demonstrate enhanced ethanol intake, stronger associations with ethanol-associated cues and contexts, and enhanced behavioral despair and anxiety that would be particularly responsive to mGlu~5~ receptor modulation.

7. Conclusions {#sec7-brainsci-09-00183}
==============

The data currently reviewed indicate that mGlu~5~ receptor modulation is a promising target for negative affect-like behavior associated with alcohol use disorders. mGlu~5~ receptor modulation is able to reduce ethanol intake, salience of ethanol-associated cues and contexts, behavioral despair, and anxiety-like activity. In humans, alcohol consumption manifests in many ways. This includes no alcohol use, light and recreational use, and dangerous levels of binging and intoxication. Currently, the literature suggests that mGlu~5~ receptors contribute to sex-specific neuroadaptations following alcohol use. These adaptations appear to be dependent upon age of onset of use, frequency of use, length of use, and length of abstinence from ethanol. Although the current studies touch on these points, the field is ripe for investigation of sex-differences, adolescent alcohol exposure, the role of alcohol dependence, and the effect of varying periods of withdrawal on the interaction of negative affect with alcohol intake and seeking. In particular, females and those exposed to alcohol during adolescence might be particularly susceptible to developing these negative affective states following protracted withdrawal from ethanol due to the role of developmental sex hormones in neuroadaptations underlying mGlu~5~ receptor signaling. The current studies also primarily focused on negative affective states following ethanol exposure. However, negative affective states often precipitate relapse. Therefore, future studies are needed to observe whether mGlu~5~ receptor modulation during periods of negative affect, such as chronic or unpredictable stressors, might work to alleviate ethanol intake. Finally, studies should consider using more than one task to observe behavioral despair and anxiety-like activity, as these phenotypes might manifest differently based on sex, age of exposure, and length of exposure or withdrawal. Although further work is required to broadly ensure the safety and efficacy of mGlu~5~ receptor modulation, the current work supports this system as a promising target for treating both ethanol-induced negative affect, as well as preventing negative affect-induced relapse.
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###### 

Details from studies on the effects of mGlu5 receptor modulation on ethanol intake in continuous access, limited access, and operant ethanol drinking paradigms.

  ------------------------------------------ ------------------------------------- ----------------------------------- -------------------------------------------------- ------------- ----------------------- ---------------------- ------------------------------
  **Continuous Access**                                                                                                                                                                                                                

  **Manipulation**                           **Average Reported Ethanol Intake**   **Treatment Details**               **Species/Strain/Sex**                             **Housing**   **Effect**              **Dose**               **Reference**

  *GRM5* mutation                            TS/TS: greater than 6.0 g/kg                                              Male & female *GRM5^TS/TS,\ TS/AA,\ AA/AA^* mice   Grouped       Increased               AA/AA                  \[[@B19-brainsci-09-00183]\]

  MTEP                                       Up to 20 g/kg                         Repeated systemic prior to access   Female B6 mice                                     Individual    Increased & Decreased   20 mg/kg               \[[@B31-brainsci-09-00183]\]

  mGlu~5~ receptor deficiency                Wild type: greater than 9.0 g/kg                                          Male Grm5^tm1Rod^ mice                                           Decreased               n/a                    \[[@B17-brainsci-09-00183]\]

  mGlu~5~ receptor knockout                  Wild type: up to 3.0 g/kg                                                 Female mGlu5^−/−^ mice                                           Decreased, no change    n/a                    \[[@B32-brainsci-09-00183]\]

  MTEP                                       Up to 5 g/kg                          Repeated systemic                   Male FH rats                                                     Decreased               2 mg/kg                \[[@B27-brainsci-09-00183]\]

  MTEP                                       Up to 15 g/kg                         Repeated systemic prior to access   Male B6 mice                                       Individual    Decreased               20 mg/kg               \[[@B31-brainsci-09-00183]\]

  MPEP                                       0.53 ± 0.05 g/kg                      Repeated systemic                   Male Wistar rats                                   Individual    Decreased               3, 10 mg/kg            \[[@B30-brainsci-09-00183]\]

  MPEP                                       Greater than 5.0 g/kg                 Repeated systemic                   Meyers rats                                        Individual    Decreased               1, 3 mg/kg             \[[@B33-brainsci-09-00183]\]

  MPEP                                       17.9 ± 8.2 g/kg                       Repeated systemic                   Male B6 mice                                       Individual    Decreased               10 mg/kg               \[[@B25-brainsci-09-00183]\]

  mGlu~5~ receptor knockdown on D1 neurons   Up to 6 g/kg                                                              Male mGlu5^KD−D1^ mice                             Individual    No change               n/a                    \[[@B16-brainsci-09-00183]\]

  mGlu~5~ receptor knockout                  Wild type: up to 2.0 g/kg                                                 Male mGlu5^−/−^ mice                                             No change               n/a                    \[[@B32-brainsci-09-00183]\]

  Impaired mGlu5/Homer interaction           Wild type: 10.84 ± 2.26 g/kg                                              Male mGlu5-F1128R mice                             Grouped       No change               n/a                    \[[@B18-brainsci-09-00183]\]

  **Limited Access**                                                                                                                                                                                                                   

  **Manipulation**                           **Average Reported Ethanol Intake**   **Treatment Details**               **Species/Strain/Sex**                             **Housing**   **Effect**              **Dose**               **Reference**

  mGlu~5~ receptor knockout                  Wild type: greater than 2.0 g/kg                                          Female mGlu5^−/−^ mice                                           Decreased               n/a                    \[[@B32-brainsci-09-00183]\]

  MTEP                                       Up to 3 g/kg                          Repeated systemic                   Female B6 mice                                     Individual    Decreased               20 mg/kg               \[[@B31-brainsci-09-00183]\]

  MTEP                                       Up to 3.5 g/kg                        Repeated systemic                   Male B6 mice                                       Individual    Decreased               10, 20 mg/kg           \[[@B31-brainsci-09-00183]\]

  MTEP                                       Up to 4.5 g/kg                        Acute intra-CeA                     Male B6 mice                                       Individual    Decreased               3 µg/side              \[[@B34-brainsci-09-00183]\]

  MPEP                                       Up to 1.5 g/kg                        Acute intra-NAc                     Male B6 mice                                       Individual    Decreased               0.1, 0.3, 1 µg/side    \[[@B18-brainsci-09-00183]\]

  mGlu~5~ receptor knockout                  Wild type: up to 1.5 g/kg                                                 Female mGlu5^−/−^ mice                                           No change               n/a                    \[[@B32-brainsci-09-00183]\]

  MTEP                                       Up to 2.0 g/kg                        Acute intra-adBNST                  Male & female *GRM5^TS/TS,\ TS/AA,\ AA/AA^* mice   Individual    No change               30 µg/side             \[[@B19-brainsci-09-00183]\]

  MPEP                                       Greater than 0.75 g/kg                Acute intra-NAc                     Male mGlu5-F1128R mice                             Individual    No change               1 µg/side              \[[@B18-brainsci-09-00183]\]

  **Operant Responding**                                                                                                                                                                                                               

  **Manipulation**                           **Average Reported Ethanol Intake**   **Treatment Details**               **Species/Strain/Sex**                             **Housing**   **Effect**              **Dose**               **Reference**

  *GRM5* mutation                            TS/TS: up to 1.5 g/kg                                                     Male & female *GRM5^TS/TS,\ TS/AA,\ AA/AA^* mice   Grouped       Increased               AA/AA                  \[[@B19-brainsci-09-00183]\]

  mGlu~5~ receptor knockdown on D1 neurons   Wild type: up to 3000 licks                                               Female mGlu5^KD−D1^ mice                           Grouped       Decreased               n/a                    \[[@B15-brainsci-09-00183]\]

  MTEP                                       Up to 80 responses                    Acute systemic                      Male FH rats                                                     Decreased               2 mg/kg                \[[@B27-brainsci-09-00183]\]

  MTEP                                       Greater than 100 responses            Acute systemic                      Male iP rats                                                     Decreased               1, 2 mg/kg             \[[@B27-brainsci-09-00183]\]

  MTEP                                       Greater than 100 responses            Acute systemic                      Male B6 mice                                       Grouped       Decreased               20, 40 mg/kg           \[[@B28-brainsci-09-00183]\]

  MTEP                                       Up to 20 responses                    Acute intra-NAc shell               Male Wistar rats                                                 Decreased               1.5 µg/side            \[[@B35-brainsci-09-00183]\]

  MTEP                                       Non-dependent: up to 30 responses\    Acute systemic                      Male Wistar rats                                   Grouped       Decreased               1, 3 mg/kg             \[[@B36-brainsci-09-00183]\]
                                             Dependent: up to 40 responses                                                                                                                                                             

  MPEP                                       Up to 80 responses                    Acute systemic                      Male iP rats                                       Individual    Decreased               3, 10 mg/kg            \[[@B24-brainsci-09-00183]\]

  MPEP                                       Greater than 8.0 g/kg                 Acute systemic                      Male B6 mice                                       Individual    Decreased               3, 10 mg/kg            \[[@B25-brainsci-09-00183]\]

  MPEP                                       Up to 5 g/kg                          Acute systemic                      Male B6 mice                                                     Decreased               3, 10 mg/kg            \[[@B26-brainsci-09-00183]\]

  MPEP                                       Greater than 0.6 g/kg                 Acute systemic                      Male iP rats                                       Pair          Decreased               3, 10 mg/kg            \[[@B29-brainsci-09-00183]\]

  MPEP                                       0.96 ± 0.22 g/kg                      Acute intra-NAc medial core         Male iP rats                                       Individual    Decreased               10 µg/side             \[[@B37-brainsci-09-00183]\]

  MTEP                                       Up to 15 responses                    Acute intra-NAc core                Male Wistar rats                                                 No change               1.5 µg/side            \[[@B35-brainsci-09-00183]\]

  MTEP                                       0.60 ± 0.1 g/kg                       Acute systemic                      iP rats                                            Pair          No change               2.5 mg/kg              \[[@B23-brainsci-09-00183]\]

  MPEP                                       1.15 ± 0.18 g/kg                      Acute intra-dorsomedial caudate     Male iP rats                                       Individual    No change               1, 3, 10 µg/side       \[[@B37-brainsci-09-00183]\]

  MPEP                                       1.02 ± 0.08 g/kg                      Acute intra-medial PFC              Male iP rats                                       Individual    No change               1, 3, 10, 30 µg/side   \[[@B37-brainsci-09-00183]\]
  ------------------------------------------ ------------------------------------- ----------------------------------- -------------------------------------------------- ------------- ----------------------- ---------------------- ------------------------------

wild-type (GRM5^TS/TS^), heterozygous mutant (GRM5^TS/AA^), homozygous mutant (GRM5^AA/AA^), C57Bl/6J (B6), Fawn Hooded (FH), central amygdala (CeA), nucleus accumbens (NAc), anterior dorsal bed nucleus of the stria terminalis (adBNST), inbred alcohol-preferring (iP), prefrontal cortex (PFC), 2-Methyl-6-(phenylethynyl)pyridine (MPEP) and 3-((2-Methyl-1,3-thiazol-4-yl)ethynyl)pyridine (MTEP).

brainsci-09-00183-t002_Table 2

###### 

Details from studies observing the effect of mGlu5 receptor modulation on cue-induced reinstatement to seek ethanol and ethanol-conditioned place preference.

  ------------------------------------------ ------------------------------------- --------------------------------------------------- -------------------------------------------------- ------------- ------------ ----------------- ------------------------------
  **Ethanol Cue-Induced Reinstatement**                                                                                                                                                                                                

  **Manipulation**                           **Average Reported Ethanol Intake**   **Treatment Details**                               **Species/Strain/Sex**                             **Housing**   **Effect**   **Dose**          **Reference**

  CDPPB                                      Up to 80 responses                    Repeated systemic, during extinction                Male Wistar rats                                   Individual    Decreased    20 mg/kg          \[[@B53-brainsci-09-00183]\]

  MTEP                                       Greater than 60 responses             Acute intra-BLA, prior to reinstatement test        Male Wistar rats                                   Individual    Decreased    3.0 µg/µl         \[[@B54-brainsci-09-00183]\]

  MTEP                                       Greater than 40 responses             Acute intra-NAc core, prior to reinstatement test   Male Wistar rats                                   Individual    Decreased    3.0 µg/µl         \[[@B54-brainsci-09-00183]\]

  MPEP                                       Up to 60 responses                    Acute systemic, prior to reinstatement test         Male iP rats                                       Pair          Decreased    1, 10 mg/kg       \[[@B55-brainsci-09-00183]\]

  MPEP                                       0.53 ± 0.05 g/kg                      Acute systemic, prior to reinstatement test         Male Long Evans rats                               Pair          Decreased    3, 10 mg/kg       \[[@B30-brainsci-09-00183]\]

  MPEP                                       2.0 g/kg                              Acute systemic, prior to reinstatement test         Male B6 mice                                       Grouped       Decreased    20 mg/kg          \[[@B56-brainsci-09-00183]\]

  MTEP                                       0.54 ± 0.04 g/kg                      Acute systemic, prior to reinstatement test         iP rats                                            Pair          No change    2.5 mg/kg         \[[@B57-brainsci-09-00183]\]

  MTEP                                       0.60 ± 0.1 g/kg                       Acute systemic, prior to reinstatement test         iP rats                                            Pair          No change    2.5 mg/kg         \[[@B23-brainsci-09-00183]\]

  **Ethanol Conditioned Place Preference**                                                                                                                                                                                             

  **Manipulation**                           **Ethanol Dose**                      **Treatment Details**                               **Species/Strain/Sex**                             **Housing**   **Effect**   **Dose**          **Reference**

  *GRM5* mutation                            1.0--3.0 g/kg                                                                             Male & female *GRM5^TS/TS,\ TS/AA,\ AA/AA^* mice   Grouped       Increased\   TS/TS\            \[[@B19-brainsci-09-00183]\]
                                                                                                                                                                                                        Decreased    AA/AA             

  mGlu~5~ receptor deficiency                1.0 g/kg                                                                                  Male Grm5^tm1Rod^ mice                                           Decreased    n/a               \[[@B17-brainsci-09-00183]\]

  MTEP                                       0.5 g/kg                              Acute systemic, prior to test                       Male Wistar rats                                   Grouped       Decreased    2.5, 5 mg/kg      \[[@B58-brainsci-09-00183]\]

  MPEP                                       2.0 g/kg                              Acute systemic, prior to test                       Male B6 mice                                       Grouped       Decreased    20 mg/kg          \[[@B56-brainsci-09-00183]\]

  MPEP                                       2.0 g/kg                              Acute systemic, prior to test                       Male B6 mice                                       Individual    Decreased    10 mg/kg          \[[@B25-brainsci-09-00183]\]

  mGlu~5~ receptor knockdown on D1 neurons   1.5 g/kg                                                                                  Male & female mGlu5^KD−D1^ mice                    Grouped       No change    n/a               \[[@B15-brainsci-09-00183]\]

  MPEP                                       2.0 g/kg                              Repeated systemic, during acquisition               Male B6 mice                                       Grouped       No change    5, 10, 20 mg/kg   \[[@B56-brainsci-09-00183]\]

  MPEP                                       2.0 g/kg                              Repeated systemic, during acquisition               Male D2 mice                                       Grouped       No change    1, 5, 20 mg/kg    \[[@B59-brainsci-09-00183]\]
  ------------------------------------------ ------------------------------------- --------------------------------------------------- -------------------------------------------------- ------------- ------------ ----------------- ------------------------------

Basolateral amygdala (BLA), nucleus accumbens (NAc), inbred preferring rat (iP), C57Bl/6J (B6), DBA/2J (D2), 3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB).

brainsci-09-00183-t003_Table 3

###### 

Details of the effects of mGlu5 receptor modulation on behavioral despair in the forced swim task.

  Manipulation   Average Reported Ethanol Intake   Treatment Details       Species/Strain/Sex        Housing   Alcohol × Drug Effect   Dose            Reference
  -------------- --------------------------------- ----------------------- ------------------------- --------- ----------------------- --------------- ------------------------------
  MTEP           4.00 ± 0.05 g/kg                  Acute systemic          Adult male B6 mice        Grouped   Rescued                 30 mg/kg        \[[@B77-brainsci-09-00183]\]
  MTEP           Greater than 4.0 g/kg             Acute systemic          Adult male B6 mice        Grouped   Rescued                 30 mg/kg        \[[@B75-brainsci-09-00183]\]
  CDPPB          Greater than 4.0 g/kg             Acute systemic          Adult male B6 mice        Grouped   Exacerbated             30 mg/kg        \[[@B75-brainsci-09-00183]\]
  MTEP           Greater than 5.0 g/kg             Acute systemic          Adolescent male B6 mice   Grouped   No change               30 mg/kg        \[[@B75-brainsci-09-00183]\]
  MTEP           Up to 7.0 g/kg                    Acute intra-NAc shell   Adolescent male B6 mice   Grouped   No change               1, 10 µg/side   \[[@B76-brainsci-09-00183]\]
  MTEP           Up to 5.0 g/kg                    Acute intra-NAc shell   Adult male B6 mice        Grouped   No change               1, 10 µg/side   \[[@B76-brainsci-09-00183]\]
  CDPPB          Greater than 5.0 g/kg             Acute systemic          Adolescent male B6 mice   Grouped   No change               30 mg/kg        \[[@B75-brainsci-09-00183]\]

C57Bl/6J (B6), nucleus accumbens (NAc).

brainsci-09-00183-t004_Table 4

###### 

Details from studies assessing anxiety-like activity following mGlu5 modulation in the elevated plus maze (EPM), light/dark box (LD), open field (OF), and marble burying (MB) tasks.

  Manipulation   Task   Average Reported Ethanol Intake   Treatment Details       Species/Strain/Sex        Housing      Alcohol × Drug Effect   Dose                       Reference
  -------------- ------ --------------------------------- ----------------------- ------------------------- ------------ ----------------------- -------------------------- ------------------------------
  MTEP           EPM    Up to 2 g/kg                      Acute systemic          Adult male Wistar rats    Grouped      Rescued                 2.5, 5 mg/kg               \[[@B92-brainsci-09-00183]\]
  MPEP           EPM    Greater than 10.0 g/kg            Acute systemic          Male Wistar rats          Individual   Rescued                 2.5, 5, 10, 20, 30 mg/kg   \[[@B93-brainsci-09-00183]\]
  MTEP           LD     Greater than 4.0 g/kg             Acute systemic          Adult male B6 mice        Grouped      Rescued                 30 mg/kg                   \[[@B75-brainsci-09-00183]\]
  MTEP           LD     Up to 5.0 g/kg                    Acute intra-NAc shell   Adult male B6 mice        Grouped      Rescued                 1 µg/side                  \[[@B76-brainsci-09-00183]\]
  CDPPB          LD     Greater than 4.0 g/kg             Acute systemic          Adult male B6 mice        Grouped      Exacerbated             30 mg/kg                   \[[@B75-brainsci-09-00183]\]
  MTEP           LD     Greater than 5.0 g/kg             Acute systemic          Adolescent male B6 mice   Grouped      No change               30 mg/kg                   \[[@B75-brainsci-09-00183]\]
  CDPPB          LD     Greater than 5.0 g/kg             Acute systemic          Adolescent male B6 mice   Grouped      No change               30 mg/kg                   \[[@B75-brainsci-09-00183]\]
  MTEP           LD     Up to 7.0 g/kg                    Acute intra-NAc shell   Adolescent male B6 mice   Grouped      No change               1, 10 µg/side              \[[@B76-brainsci-09-00183]\]
  MPEP           OF     Greater than 10.0 g/kg            Acute systemic          Male Wistar rats          Individual   Rescued                 2.5, 5, 10 mg/kg           \[[@B93-brainsci-09-00183]\]
  MTEP           MB     Greater than 4.0 g/kg             Acute systemic          Adult male B6 mice        Grouped      Rescued                 30 mg/kg                   \[[@B75-brainsci-09-00183]\]
  MTEP           MB     Up to 5.0 g/kg                    Acute intra-NAc shell   Adult male B6 mice        Grouped      Rescued                 1 µg/side                  \[[@B76-brainsci-09-00183]\]
  MTEP           MB     Up to 7.0 g/kg                    Acute intra-NAc shell   Adolescent male B6 mice   Grouped      Rescued                 10 µg/side                 \[[@B76-brainsci-09-00183]\]
  MTEP           MB     Greater than 5.0 g/kg             Acute systemic          Adolescent male B6 mice   Grouped      Decreased               30 mg/kg                   \[[@B75-brainsci-09-00183]\]
  CDPPB          MB     Greater than 5.0 g/kg             Acute systemic          Adolescent male B6 mice   Grouped      Increased               30 mg/kg                   \[[@B75-brainsci-09-00183]\]
  CDPPB          MB     Greater than 4.0 g/kg             Acute systemic          Adult male B6 mice        Grouped      No change               30 mg/kg                   \[[@B75-brainsci-09-00183]\]

Elevated plus maze (EPM), light/dark box (LD), C57Bl/6J (B6), nucleus accumbens (NAc), open field (OF), marble burying (MB).
